Bernd Winterhalter

Corporate Officer/Principal at

CureVac SE

67 year

Health Technology

Consumer Services

Profile

Bernd Winterhalter is currently the Chief Development Officer at CureVac SE since 2019.
Prior to this, he worked as the Executive Medical Director at Bristol-Myers Squibb GmbH & Co. KGaA from 2004 to 2018 and as the Vice President-Medical, Science & Health Economics at Pharmacia GmbH from 1997 to 2003.
He also briefly served as the Chief Development Officer at CureVac NV from 2019 to 2021.
Dr. Winterhalter holds a doctorate degree from the University of Freiburg.

Bernd Winterhalter active positions

Companies	Position	Start
CureVac SE CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies	Corporate Officer/Principal	30/11/2019

All active positions of Bernd Winterhalter

Former positions of Bernd Winterhalter

Companies	Position	End
CUREVAC	Corporate Officer/Principal	31/01/2021
Bristol-Myers Squibb GmbH & Co. KGaA Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical medicines	Chief Tech/Sci/R&D Officer	31/12/2017
Pharmacia GmbH	Chief Tech/Sci/R&D Officer	31/12/2002

See the detail of Bernd Winterhalter's experience

Training of Bernd Winterhalter

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Bernd Winterhalter's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
CureVac SE CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies	Health Technology
University of Freiburg University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Pharmacia GmbH
Bristol-Myers Squibb GmbH & Co. KGaA Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical medicines	Health Technology
CureVac NV CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies	Health Technology